Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3738studies shown
Showing 2,851-2,875 of 3,738
RecruitingISRCTN55488371

Computerised Cognitive Remediation Therapy for Schizophrenia

This study is looking at whether a digital support tool can help people with psychosis. Participants take part in a digital support tool and complete follow-up assessments.

SchizophreniaOther
Countries
United Kingdom
Sponsor
South London and Maudsley NHS Trust (UK)
Condition
Schizophrenia
RecruitingISRCTN25898179

Rehabilitation Effectiveness for Activities for Life

This study is looking at whether Intervention arm: Services will receive the GetREAL intervention as developed in Phase 2 can help people with psychosis. Participants take part in Intervention arm: Services will receive the GetREAL intervention as developed in Phase 2 and complete follow-up assessments.

SchizophreniaOther
Countries
United Kingdom
Sponsor
University College London (UK)
Condition
Schizophrenia
RecruitingISRCTN42412532

Treatment Of Cognitive deficits in schizophrenia with Tolcapone And Pergolide

This study is looking at whether TOCTAP is a randomised, three-armed double-blind study with 60 patients suffering from schizophrenia, using DSM-IV diagnostic criteria can help people with Schizophrenia, cognitive functions, Mental and Behavioural Disorders, or Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
Germany
Sponsor
RWTH Aachen University (Germany)
Condition
Schizophrenia
RecruitingISRCTN84216587

Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia

This study is looking at whether a digital support tool can help people with Schizophrenia or Mental and Behavioural Disorders. Participants take part in a digital support tool and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
Queen Mary University of London and Barts and the London NHS Trust (UK)
Condition
Schizophrenia
RecruitingISRCTN32434568

OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia

This study is looking at whether a digital support tool can help people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom, Finland, Italy
Sponsor
University of Oxford (UK)
Condition
Schizophrenia
RecruitingISRCTN94846422

An intervention to improve psychiatrist-patient communication

This study is looking at whether a digital support tool can help people with Schizophrenia/schizoaffective disorder, Mental and Behavioural Disorders, or Schizophrenia. Participants take part in a digital support tool and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
Queen Mary University of London (UK)
Condition
Schizophrenia
RecruitingISRCTN74919979

Information technology in mental health

This study is looking at a support or therapy approach for people with Schizophrenia, schizotypal disorders or delusional disorders, Mental and Behavioural Disorders, or Schizophrenia. Participants take part in the program or support approach and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
Finland
Sponsor
Academy of Finland (Finland)
Condition
Schizophrenia
RecruitingISRCTN54975957

Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial

This study is looking at whether Mirtazapine was added to the on-going pharmacotherapy with risperidone in the mirtazapine group can help people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOther
Countries
South Korea
Sponsor
Bundang CHA Hospital (South Korea)
Condition
Schizophrenia
RecruitingISRCTN61794329

Does oral N-acetyl-cysteine (NAC) improve schizophrenia symptoms?

This observational study is following people with Early phase psychosis, Mental and Behavioural Disorders, or Schizophrenia to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

SchizophreniaOther
Countries
Switzerland, United States
Sponsor
Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland)
Condition
Schizophrenia
RecruitingISRCTN56877013

A randomised trial comparing the clinical and cost effectiveness of usual, facility based care compared to an additional collaborative community care package for people and their families living with schizophrenia in India

This study is looking at whether a digital support tool can help people with Mental health/schizophrenia, Mental and Behavioural Disorders, or Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom, India
Sponsor
Kings College London (UK)
Condition
Schizophrenia
RecruitingISRCTN50247539

Reflex

This study is looking at whether Current information as of 10/12/09: Patients will have 12 one-hour group therapy sessions with a psychologist can help people with Psychic disorders, schizophrenia and other psychosis, Mental and Behavioural Disorders, or Schizophrenia. Participants take part in Current information as of 10/12/09: Patients will have 12 one-hour group therapy sessions with a psychologist and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
Netherlands
Sponsor
University Medical Center Groningen (UMCG) (Netherlands)
Condition
Schizophrenia
RecruitingISRCTN64695913

Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)

This study is looking at whether There is a 14-day screening period and a 3 to 7-day placebo washout period before randomisation of the participants for the trial can help people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
Colombia, Germany, India, Philippines, Romania, Russian Federation, Ukraine, United States
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
RecruitingISRCTN44297014

A phase III randomised, double-blind, active comparator-controlled clinical trial to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)

This study is testing a medication approach for people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
Colombia, Germany, India, Philippines, Romania, Russian Federation, Ukraine, United States
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
RecruitingISRCTN62599190

Comparison of training methods in dual diagnosis (mental health and substance use) treatment for community mental health teams

This study is looking at whether This is an intention to treat, repeated measure within subjects randomised trial can help people with Schizophrenia, co-morbid drug and alcohol dependence, Mental and Behavioural Disorders, or Schizophrenia. Participants take part in the program and complete follow-up questionnaires or assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
University College London (UK)
Condition
Schizophrenia
RecruitingISRCTN23263429

Efficacy of the BELA weight management programme to prevent increase of weight in schizophrenic patients treated with olanzapin (BELA = movement - nutrition - learning - accepting)

This study is looking at whether psychoeducation can help people with Schizophrenia or Mental and Behavioural Disorders. Participants take part in psychoeducation and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
Germany
Sponsor
Heinrich-Heine University (Germany)
Condition
Schizophrenia
RecruitingISRCTN33909010

A phase 3 randomised placebo- and active comparator-controlled, clinical trial to study the safety and efficacy of two doses of lurasidone HCL in acutely psychotic patients with schizophrenia

This study is testing a medication approach for people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom, Bulgaria, Colombia, India, Lithuania, Peru, Philippines, Serbia
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
RecruitingISRCTN16838597

A phase three randomised, placebo-controlled, clinical trial to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic patients with schizophrenia

This study is testing a medication approach for people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom, France, India, Malaysia, Romania, Russian Federation, Ukraine, United States
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
RecruitingISRCTN97049967

Phase 3 long-term safety, tolerability and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder

This study is testing a medication approach for people with Schizophrenia or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
United Kingdom, Argentina, Brazil, Chile, Croatia, Israel, South Africa, Thailand
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
RecruitingISRCTN02658871

Secondary PREVENTion of schizophrenia: a randomised controlled trial

This study is looking at whether psychoeducation can help people with Prodromal schizophrenia, Mental and Behavioural Disorders, or Schizotypal disorder. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 49 Years
Countries
Germany
Sponsor
University of Cologne (Germany)
Condition
Schizophrenia
RecruitingISRCTN93378085

Pilot study for a new treatment of schizophrenia: a double-blind crossover transcranial magnetic stimulation

This study is looking at care and outcomes for people with Schizophrenia or Mental and Behavioural Disorders. Some participants may receive sham treatment instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United Kingdom
Sponsor
Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Condition
Schizophrenia
RecruitingISRCTN19638644

How can rehospitalisations of patients with schizophrenia be avoided? A comparison between different compliance programs

This study is looking at whether psychoeducation can help people with Schizophrenia or schizoaffective disorder, Mental and Behavioural Disorders, or Schizophrenia, schizotypal and delusional disorders. Participants take part in psychoeducation and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 67 Years
Countries
Germany
Sponsor
Technical University Munich (Germany)
Condition
Schizophrenia
RecruitingISRCTN95205723

Metacognitive skill training for schizophrenic patients

This study is looking at whether Experimental intervention: MetaCognitive skill Training (MCT) focusing on delusion-relevant metacognitive biases in schizophrenia can help people with Schizophrenia or Mental and Behavioural Disorders. Participants take part in Experimental intervention: MetaCognitive skill Training (MCT) focusing on delusion-relevant metacognitive biases in schizophrenia and complete follow-up assessments.

SchizophreniaOther
Countries
Germany
Sponsor
German Research Foundation (DFG)/Federal Ministry of Education and Research (BMBF) (Germany)
Condition
Schizophrenia
RecruitingISRCTN29242879

Cognitive behavioural treatment for persistent positive symptoms in psychotic disorders

This study is looking at whether Cognitive Behavioural Treatment versus Supportive Therapy can help people with psychosis or Mental and Behavioural Disorders. Participants take part in Cognitive Behavioural Treatment versus Supportive Therapy and complete follow-up assessments.

SchizophreniaOther
Countries
Germany
Sponsor
University Hospital Tuebingen (Germany)
Condition
Schizophrenia
Recruiting | Clinical Trials | HopeStage Research